Riluzole
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Posttraumatic Stress Disorder
Conditions
Posttraumatic Stress Disorder
Trial Timeline
Mar 16, 2017 → Mar 16, 2019
NCT ID
NCT04630444About Riluzole
Riluzole is a phase 1 stage product being developed by Brain Biotech for Posttraumatic Stress Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT04630444. Target conditions include Posttraumatic Stress Disorder.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04630444 | Phase 1 | Completed |
Competing Products
8 competing products in Posttraumatic Stress Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine hydrochloride | Eli Lilly | Phase 3 | 77 |
| Nepicastat + Placebo | Johnson & Johnson | Phase 2 | 52 |
| Placebo + sertraline | Johnson & Johnson | Approved | 85 |
| Adjunctive asenapine | Merck | Approved | 85 |
| sertraline (Zoloft) | Pfizer | Pre-clinical | 22 |
| Ziprasidone | Pfizer | Approved | 84 |
| Methylphenidate Hydrochloride 20 mg + Placebo Capsule + Galantamine 12 mg | Brain Biotech | Phase 2 | 44 |
| High THC/Low CBD Cannabis + High THC/High CBD Cannabis + Low THC/Low CBD Cannabis | Tilray | Phase 2 | 47 |